Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma

Leslie E. Fox Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610-0126.

Search for other papers by Leslie E. Fox in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Robert C. Rosenthal Veterinary Specialists, 2816 Monroe Ave, Rochester, NY 14618.

Search for other papers by Robert C. Rosenthal in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Robert R. King Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610-0126.

Search for other papers by Robert R. King in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Paula B. Levine Present address is 3252 Oakbrook Lane, Clarkson, GA 30021.

Search for other papers by Paula B. Levine in
Current site
Google Scholar
PubMed
Close
 DVM
,
David M. Vail Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by David M. Vail in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Stuart C. Helfand Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by Stuart C. Helfand in
Current site
Google Scholar
PubMed
Close
 DVM
,
E. Gregory MacEwen Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by E. Gregory MacEwen in
Current site
Google Scholar
PubMed
Close
 VMD
,
Roman Perez-Soler Kaplan Comprehensive Cancer Center, New York University Medical School, New York, NY 10816.

Search for other papers by Roman Perez-Soler in
Current site
Google Scholar
PubMed
Close
 MD
,
Maron Calderwood-Mays Florida Vet Path, Gainesville, FL 32603.

Search for other papers by Maron Calderwood-Mays in
Current site
Google Scholar
PubMed
Close
 VMD, PhD
, and
Ilene D. Kurzman Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706.

Search for other papers by Ilene D. Kurzman in
Current site
Google Scholar
PubMed
Close
 MA, MS, EdD

Abstract

Objective—To determine clinical response and toxic effects of cis-bis-neodecanoato-trans-R,R-1,2- diaminocyclohexane platinum (II) (L-NDDP) administered IV at escalating doses to cats with oral squamous cell carcinoma (SCC).

Animals—18 cats with oral SCC.

Procedure—Cats that failed to respond to conventional treatment or had nonresectable tumors were included. Data included a CBC, serum biochemical analyses, urinalysis, cytologic examination of a fineneedle aspirate of enlarged lymph nodes, and thoracic and oral radiographs for clinical staging. A starting dose (75 to 100 mg/m2 of L-NDDP) was administered IV. At 21-day intervals, subsequent doses increased by the rate of 5 or 10 mg/m2. Response was evaluated every 21 days by tumor measurement and thoracic radiography. Quality of life was assessed by owners, using a performance status questionnaire.

Results—On average, cats received 2 treatments. Toxicoses included an intermittent, acute anaphylactoid- parasympathomimetic reaction, lethargy or sedation (≤ 24 hours), inappetence or signs of depression (≤ 72 hours), mild to moderate increase in hepatic enzyme activity, and melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Performance status surveys indicated normal behavior and grooming or decreased activity and self-care (19/20 assessments), ate well with or without assistance (15/20), and did not lose weight (15/20). Median survival time was 59.8 days (mean, 54.1 days).

Conclusions and Clinical Relevance—L-NDDP was ineffective for treatment of cats with oral SCC. None of the cats had a complete or partial remission. Acute toxicoses and poor therapeutic response limit therapeutic usefulness of L-NDDP in cats, unless dosage, frequency, and administration procedures can be improved. (Am J Vet Res 2000;61: 791–795)

Abstract

Objective—To determine clinical response and toxic effects of cis-bis-neodecanoato-trans-R,R-1,2- diaminocyclohexane platinum (II) (L-NDDP) administered IV at escalating doses to cats with oral squamous cell carcinoma (SCC).

Animals—18 cats with oral SCC.

Procedure—Cats that failed to respond to conventional treatment or had nonresectable tumors were included. Data included a CBC, serum biochemical analyses, urinalysis, cytologic examination of a fineneedle aspirate of enlarged lymph nodes, and thoracic and oral radiographs for clinical staging. A starting dose (75 to 100 mg/m2 of L-NDDP) was administered IV. At 21-day intervals, subsequent doses increased by the rate of 5 or 10 mg/m2. Response was evaluated every 21 days by tumor measurement and thoracic radiography. Quality of life was assessed by owners, using a performance status questionnaire.

Results—On average, cats received 2 treatments. Toxicoses included an intermittent, acute anaphylactoid- parasympathomimetic reaction, lethargy or sedation (≤ 24 hours), inappetence or signs of depression (≤ 72 hours), mild to moderate increase in hepatic enzyme activity, and melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Performance status surveys indicated normal behavior and grooming or decreased activity and self-care (19/20 assessments), ate well with or without assistance (15/20), and did not lose weight (15/20). Median survival time was 59.8 days (mean, 54.1 days).

Conclusions and Clinical Relevance—L-NDDP was ineffective for treatment of cats with oral SCC. None of the cats had a complete or partial remission. Acute toxicoses and poor therapeutic response limit therapeutic usefulness of L-NDDP in cats, unless dosage, frequency, and administration procedures can be improved. (Am J Vet Res 2000;61: 791–795)

Advertisement